[Enhancing antitumor activity of tumor-draining lymph node cells by autologous dendritic cells].
OBJECTIVE
To enhance antitumor activity of tumor-draining lymph node(TDLN) cells by autologous dendritic cells(DCs) in-vitro.


METHODS
Peripheral blood mononuclear cells(PBMCs) were isolated from the patients with gastric adenocarcinoma and induced with GM-CSF, IL-4 and TNF-alpha to obtain mature DCs which were then sensitized by autologous tumor lysate. TDLN cells were isolated and purified from lymph nodes of the patients and incubated with IL-2. Then we designed three experiment groups: (1)first group: TDLN cells activated by sensitized DCs; (2) second group:TDLN cells activated by autologous tumor lysate; (3)third group: TDLN cells alone, which were used as control. Cytotoxic activity of TDLN cells to gastric adenocarcinoma cell line KATO3 and human melanoma cell line A375 were compared between 3 groups.


RESULTS
The cytotoxicity of TDLN cells activated by sensitized DCs to KATO3 cells was significantly stronger than that of TDLN cells activated by autologous tumor lysate or TDLN cells alone. In contrast, for A375 cells, cytotoxic activities of three TDLN cells had no significant difference.


CONCLUSIONS
Specific antitumor activity of TDLN cells can be enhanced significantly by activated autologous DCs.
Peng
Zheng
Z
Department of General Surgery, General Hospital of PLA, Beijing 100853, China. pengzham@yahoo.com.cn
Li
Rong
R
Li
Li
L
Zhang
Lei
L
Jin
Ting
T
D000230:Adenocarcinoma / Q000473:pathology; D016516:CD4-CD8 Ratio; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000473:pathology*; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor